#USA #New York #Class Action #ESSA Pharma #EPIX

Class Action Lawsuit Against ESSA Pharma Inc.

The Gross Law Firm has recently made a significant announcement for shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). If you were a shareholder during the class period from December 12, 2023, to October 31, 2024, this information is particularly relevant to you. The firm is encouraging those affected to reach out regarding the possibility of being appointed as a lead plaintiff in the lawsuit, although doing so is not a requirement to seek recovery.

Details of the Allegations

The allegations against ESSA Pharma Inc. center on claims that the company misrepresented its drug therapies. Specifically, it is asserted that the combination of masofaniten and enzalutamide did not show the expected efficacy compared to using enzalutamide alone. Notably, crucial elements of the company's claims about the M-E Combination Study, which was designed to address prostate cancer treatments, have also come under scrutiny.

Investors were misled, according to legal representatives, as the company purportedly overstated masofaniten's clinical, regulatory, and market potential. As a result, the essential public statements regarding the drug and its effectiveness were materially flawed.

Key Dates

Shareholders should be aware that March 25, 2025, is a critical date for this case. Those wishing to join the class action must register their details before this deadline to ensure they have the opportunity to participate in any potential recovery efforts.

Steps for Affected Shareholders

To proceed, shareholders are prompted to register their information through the Gross Law Firm's designated online portal. Once registered, they will gain access to portfolio monitoring tools that will keep them updated throughout the legal proceedings ahead.

Why Choose The Gross Law Firm?

The Gross Law Firm is a reputable name in the world of class action lawsuits, dedicated to helping investors who have fallen victim to fraudulent and deceptive business practices. The firm takes pride in protecting the rights of shareholders by advocating for transparency and ethical practices in the corporate landscape. Their commitment ensures that companies remain accountable for their actions.

Contact Information

For those impacted or interested in joining the class action, further information can be obtained by contacting:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Email: [email protected]
Phone: (646) 453-8903

As this situation develops, it is critical for shareholders to act swiftly and ensure that their voices are heard in this pivotal case. Failure to register may result in the loss of the opportunity to seek justice and possible financial recovery due to the alleged misconduct by ESSA Pharma Inc.